Cargando…

Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma

BACKGROUND: Invasive adenocarcinoma intraoperatively underestimated as adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) based on frozen section (FS) is more likely to undergo insufficient resection. We aimed to investigate the predictors of upstage and treatment strategies for...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Hang, Gu, Chang, She, Yunlang, Xu, Long, Yang, Ping, Xie, Huikang, Zhao, Shengnan, Wu, Chunyan, Xie, Dong, Chen, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867766/
https://www.ncbi.nlm.nih.gov/pubmed/33569291
http://dx.doi.org/10.21037/tlcr-20-828
_version_ 1783648337595990016
author Su, Hang
Gu, Chang
She, Yunlang
Xu, Long
Yang, Ping
Xie, Huikang
Zhao, Shengnan
Wu, Chunyan
Xie, Dong
Chen, Chang
author_facet Su, Hang
Gu, Chang
She, Yunlang
Xu, Long
Yang, Ping
Xie, Huikang
Zhao, Shengnan
Wu, Chunyan
Xie, Dong
Chen, Chang
author_sort Su, Hang
collection PubMed
description BACKGROUND: Invasive adenocarcinoma intraoperatively underestimated as adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) based on frozen section (FS) is more likely to undergo insufficient resection. We aimed to investigate the predictors of upstage and treatment strategies for stage IA invasive adenocarcinoma after sublobar resection for AIS and MIA. METHODS: We identified 2,006 patients from January 2012 to December 2016 with early-stage lung adenocarcinoma who underwent sublobar resection based on FS diagnosis to guide surgical decision-making. All FS were categorized into three groups in real-time: (I) atypical adenomatous hyperplasia (AAH), (II) AIS, and (III) MIA. RESULTS: A total of 272 (13.5%, 272/2,006) cases were upstaged in the final pathology (FP) diagnosis (82 AAH to AIS, 127 AIS to MIA, and nine AIS and 54 MIA to invasive adenocarcinoma), and most upstage cases (64.3%, 175/272) were attributed to sampling error. Multivariate logistic regression showed that tumor size ≥1 cm was the only independent predictor of upstage. The upstage of 209 cases to AIS or MIA had no influence on the therapy because the extent of their resection was enough. Of the 63 cases upstaged to invasive adenocarcinoma, only 13 cases agreed to receive complementary treatment: five patients underwent complementary lobectomy, and seven patients received chemotherapy. Two invasive adenocarcinoma cases without complementary treatment experienced a local recurrence after surgery. No recurrence was observed in AAH, AIS and MIA. No patient died until December 01, 2019. CONCLUSIONS: Timely complementary treatment is encouraged in AIS/MIA upstaged to invasive adenocarcinoma based on the FP after sublobar resection to avoid local recurrence. Pathologists should be more cautious about AIS and MIA with tumor size ≥1 cm to avoid underestimation and potentially insufficient resection.
format Online
Article
Text
id pubmed-7867766
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78677662021-02-09 Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma Su, Hang Gu, Chang She, Yunlang Xu, Long Yang, Ping Xie, Huikang Zhao, Shengnan Wu, Chunyan Xie, Dong Chen, Chang Transl Lung Cancer Res Original Article BACKGROUND: Invasive adenocarcinoma intraoperatively underestimated as adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) based on frozen section (FS) is more likely to undergo insufficient resection. We aimed to investigate the predictors of upstage and treatment strategies for stage IA invasive adenocarcinoma after sublobar resection for AIS and MIA. METHODS: We identified 2,006 patients from January 2012 to December 2016 with early-stage lung adenocarcinoma who underwent sublobar resection based on FS diagnosis to guide surgical decision-making. All FS were categorized into three groups in real-time: (I) atypical adenomatous hyperplasia (AAH), (II) AIS, and (III) MIA. RESULTS: A total of 272 (13.5%, 272/2,006) cases were upstaged in the final pathology (FP) diagnosis (82 AAH to AIS, 127 AIS to MIA, and nine AIS and 54 MIA to invasive adenocarcinoma), and most upstage cases (64.3%, 175/272) were attributed to sampling error. Multivariate logistic regression showed that tumor size ≥1 cm was the only independent predictor of upstage. The upstage of 209 cases to AIS or MIA had no influence on the therapy because the extent of their resection was enough. Of the 63 cases upstaged to invasive adenocarcinoma, only 13 cases agreed to receive complementary treatment: five patients underwent complementary lobectomy, and seven patients received chemotherapy. Two invasive adenocarcinoma cases without complementary treatment experienced a local recurrence after surgery. No recurrence was observed in AAH, AIS and MIA. No patient died until December 01, 2019. CONCLUSIONS: Timely complementary treatment is encouraged in AIS/MIA upstaged to invasive adenocarcinoma based on the FP after sublobar resection to avoid local recurrence. Pathologists should be more cautious about AIS and MIA with tumor size ≥1 cm to avoid underestimation and potentially insufficient resection. AME Publishing Company 2021-01 /pmc/articles/PMC7867766/ /pubmed/33569291 http://dx.doi.org/10.21037/tlcr-20-828 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Su, Hang
Gu, Chang
She, Yunlang
Xu, Long
Yang, Ping
Xie, Huikang
Zhao, Shengnan
Wu, Chunyan
Xie, Dong
Chen, Chang
Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title_full Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title_fullStr Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title_full_unstemmed Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title_short Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
title_sort predictors of upstage and treatment strategies for stage ia lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867766/
https://www.ncbi.nlm.nih.gov/pubmed/33569291
http://dx.doi.org/10.21037/tlcr-20-828
work_keys_str_mv AT suhang predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT guchang predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT sheyunlang predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT xulong predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT yangping predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT xiehuikang predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT zhaoshengnan predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT wuchunyan predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT xiedong predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma
AT chenchang predictorsofupstageandtreatmentstrategiesforstageialungcancersaftersublobarresectionforadenocarcinomainsituandminimallyinvasiveadenocarcinoma